Metformin for Knee Arthritis: Can a Diabetes Drug Reduce Joint Pain?
- 4 days ago
- 5 min read
Written by Dr. Jeffrey Peng, MD — Board-Certified Sports Medicine Physician
Published: March 2, 2026 | Last Updated: March 2, 2026
If you or someone you know struggles with knee pain from arthritis, the possibility that a widely used diabetes medication could provide relief may change how you think about treatment options. Metformin, prescribed to more than 150 million people worldwide for type 2 diabetes, has recently drawn significant attention from researchers exploring its potential benefits for knee osteoarthritis. A landmark randomized clinical trial published in JAMA in 2025 provides some of the first high-quality evidence on this topic — and the results are encouraging.
As a sports medicine physician, I work with patients managing knee arthritis every day in my practice. In this post, I will break down the key findings from this clinical trial, explain who might benefit most, and discuss how metformin fits into the broader landscape of non-surgical arthritis management.
Watch the Full Video
What Is Knee Osteoarthritis and Why Is It So Hard to Treat?
Knee osteoarthritis is one of the most prevalent joint conditions worldwide, affecting hundreds of millions of people. It occurs when the articular cartilage — the smooth, protective tissue lining the ends of the bones within the knee joint — gradually deteriorates over time. This breakdown leads to pain, stiffness, swelling, and progressive difficulty with everyday activities such as walking, climbing stairs, and standing for extended periods.
What makes knee osteoarthritis particularly challenging is that it is not simply a "wear and tear" condition. Excess body weight contributes significantly — not only through increased mechanical load on the joint, but also through systemic metabolic changes. Obesity promotes chronic low-grade inflammation and disrupts normal glucose and lipid metabolism, creating an internal environment that accelerates cartilage damage and intensifies joint pain. This connection between metabolic health and arthritis progression has led researchers to explore treatments that target these underlying pathways rather than simply masking symptoms.
Current standard treatments for knee osteoarthritis — including anti-inflammatory medications, physical therapy, injection therapies, and in severe cases joint replacement surgery — primarily focus on symptom management. Most of these options provide temporary relief and do not halt the progression of the disease. This reality has motivated the search for new therapeutic approaches, particularly those that address the inflammatory and metabolic factors driving the condition. That is where metformin enters the picture.
Why Are Researchers Studying Metformin for Knee Arthritis?
Metformin has been used to treat type 2 diabetes for over six decades and remains one of the most widely prescribed medications in the world. Its primary mechanism involves reducing hepatic glucose production and improving insulin sensitivity, which helps regulate blood sugar levels. However, researchers have identified several additional properties that make metformin a compelling candidate for arthritis research.
First, metformin possesses anti-inflammatory effects that may help reduce the chronic inflammation implicated in osteoarthritis progression. Second, it promotes modest weight loss and improves lipid metabolism — both directly relevant for patients whose knee arthritis is exacerbated by excess body weight. Third, preclinical studies have suggested that metformin may have direct cartilage-protective effects, potentially slowing structural joint damage at the cellular level.
These overlapping mechanisms — anti-inflammatory, metabolic, and potentially chondroprotective — provided a strong scientific rationale for testing metformin in patients with knee osteoarthritis, particularly those who are overweight or obese.
What Did the JAMA Clinical Trial Find?
The pivotal trial, conducted by Pan et al. (2025) and published in JAMA, was a randomized, double-blind, placebo-controlled study — the gold standard of clinical research design. Researchers recruited 107 participants with symptomatic knee osteoarthritis and a body mass index (BMI) of 25 or higher from the community in Victoria, Australia. Participants were randomly assigned to receive either extended-release metformin (titrated up to 2,000 milligrams per day) or an identical placebo over six months.
The primary outcome was change in knee pain measured on a 100-millimeter visual analog scale (VAS). At the six-month mark, the metformin group experienced a mean pain reduction of 31.3 millimeters compared to 18.9 millimeters in the placebo group — a statistically significant between-group difference of 11.4 millimeters (95% CI: −20.1 to −2.6; P = 0.01). This corresponded to a moderate effect size (standardized mean difference) of 0.43. Notably, improvements in pain, stiffness, and knee function were not yet apparent at the three-month assessment but became clearly evident by six months.
On the safety front, metformin was well tolerated overall. The most common adverse events were gastrointestinal in nature: diarrhea occurred in 15% of the metformin group versus 8% on placebo, and abdominal discomfort in 13% versus 9%. No serious adverse events were attributed to the medication, and 82% of participants completed the full six-month trial.
What Do These Results Mean for Patients?
The moderate pain reduction achieved with metformin is clinically noteworthy. To put it in perspective, this effect size is comparable to — and in some analyses larger than — the benefits seen with commonly used nonsteroidal anti-inflammatory drugs (NSAIDs) for knee osteoarthritis. While metformin is not a cure, these findings suggest it could be a meaningful addition to the treatment toolbox, particularly for patients whose arthritis is complicated by overweight or obesity.
The delayed onset of benefit — becoming apparent only after several months of treatment — aligns with what we would expect from a medication that works through gradual anti-inflammatory and metabolic pathways rather than through direct, immediate pain relief. In my practice, I often counsel patients that treatments targeting the underlying biology of arthritis may take time to produce noticeable improvements. This trial reinforces that message: metformin requires patience to see results.
It is also important to acknowledge the study’s limitations. This was a relatively small trial with 107 participants, conducted via telemedicine, meaning that some measurements — including weight and certain arthritis features — relied on patient self-reporting. Larger, longer-term studies are needed to confirm these findings, determine the optimal treatment duration, and identify which patient populations benefit most.
How Does Metformin Fit Into a Knee Arthritis Treatment Plan?
For patients with knee osteoarthritis who are overweight or obese, metformin could potentially complement standard non-surgical treatments. It is not intended to replace evidence-based therapies such as physical therapy, structured exercise programs, weight management strategies, or injection therapies like PRP or hyaluronic acid — but rather to work alongside them as part of a comprehensive management approach.
Because metformin is already widely prescribed, generally affordable, and has a well-established safety profile spanning decades of clinical use, it represents a relatively low-barrier option that clinicians may consider discussing with appropriate patients. However, it is important to recognize that metformin is not suitable for everyone. Kidney function, concurrent medications, and individual health factors must be carefully evaluated before starting metformin for any off-label indication. This is a conversation to have with your physician.
If you are living with knee arthritis and want to learn more about the full range of non-surgical treatment options available — from injections and exercise programs to dietary strategies and regenerative therapies — I encourage you to explore my comprehensive resources on knee arthritis management.
References
Pan F, Wang Y, Lim YZ, et al. Metformin for Knee Osteoarthritis in Patients With Overweight or Obesity: A Randomized Clinical Trial. JAMA. 2025;333(20):1804-1812. doi:10.1001/jama.2025.3471
Disclaimer: This content is for educational purposes only and does not substitute for the medical advice of a physician. The information presented reflects the opinion of Dr. Jeffrey Peng and does not represent the views of his employers or affiliated hospital systems. Always consult with your healthcare provider before starting any new medication or treatment plan.
Comments